Affinity DataEC50: 5.35E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 6.60E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 4.00E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 6.83E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.63E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 2.52E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 4.24E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 7.10E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.03E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 6.92E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 8.83E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 3.16E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 6.28E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 2.26E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 3.75E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 5.75E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 4.18E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 9.23E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 9.53E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.35E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 6.85E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.51E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 1.97E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 4.15E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 3.63E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 2.56E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 2.02E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 2.25E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 2.95E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 6.26E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 8.85E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 4.89E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 4.06E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 3.34E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 2.89E+4nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 6.02E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 3.61E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 3.92E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair
Affinity DataEC50: 5.00E+3nMAssay Description:The activities of compounds of the invention in inducing erythropoietin (EPO) production were assessed by using human live cancer cell strain Hep3B (...More data for this Ligand-Target Pair